Hipocalcemia e hiperparatiroidismo extremos tras denosumab. ¿Es seguro este fármaco en la enfermedad renal crónica?

Nefrologia

Volumn 34, Issue 4, 2014, Pages 542-544

  Sirvent, Ana E ^a   Enríquez, Ricardo ^a   Sánchez, María ^a   González, César ^a   Millán, Isabel ^a   Amorós, Francisco ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; DENOSUMAB;

AGED; CASE REPORT; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; CONTRAINDICATIONS; FEMALE; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; SEVERITY OF ILLNESS INDEX;

AGED; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; FEMALE; HUMANS; HYPERPARATHYROIDISM; HYPOCALCEMIA; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84905158420     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2014.Mar.12383     Document Type: Letter

References (8)

1. Martín-Baez IM, Blanco-García R, Alonso-Suárez M, Cossio-Aranibar C, Beato-Coo LV, Fernández-Fleming F. Severe hypocalcaemia post-denosumab. Nefrologia 2013;33:614-5.
2. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011;26:1829-35.
3. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012;27:1471-9.
4. Ott SM. Therapy for patients with CKD and low bone mineral density. Nat Rev Nephrol 2013;9:681-92.
5. Torregrosa JV. Dramatic increase in parathyroid hormone and hypocalcemia after denosumab in a kidney transplant patient. Clin Kidney J 2013;6:122.
6. McCormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012;60:626-8.
7. Farinola N, Kanjanapan Y. Denosumabinduced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Intern Med J 2013;43:1243-6.
8. Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, et al. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 2013;36:1622-6.